The FDA recently approved the supplemental biologics license application for teclistamab (Tecvayli; Johnson & Johnson) to treat relapsed/refractory multiple myeloma on a biweekly dosing schedule.

Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT ...

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage. This ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer and overweight or obesity had better outcomes with immune checkpoint inhibitors than ...